Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Company Overview

Eledon Pharmaceuticals is a clinical‐stage biotechnology company focused on developing novel cell‐based therapies for rare hematological disorders. The company’s lead candidate, BIVV003, is an investigational, mesenchymal‐like placental cell therapy designed to address the underlying pathology of sickle cell disease (SCD) and transfusion‐dependent beta‐thalassemia (TDT). By harnessing the immunomodulatory and tissue‐supportive properties of placental cells, Eledon aims to reduce vaso‐occlusive events, chronic hemolysis and transfusion requirements in affected patients.

In preclinical studies, BIVV003 demonstrated an ability to modulate inflammatory cascades and promote reparative processes in the bone marrow and vasculature. The company is advancing its ongoing Phase 1/2 program to assess safety, tolerability and preliminary efficacy in individuals living with SCD and TDT. Eledon’s pipeline also includes additional indications for rare blood disorders, leveraging its proprietary cell culture and expansion platform to support scalable manufacturing and consistent product quality.

Founded in 2016, Eledon Pharmaceuticals is headquartered in San Carlos, California, and maintains research collaborations and clinical trial sites across North America and Europe. The executive team combines deep expertise in cell therapy, hematology and regulatory affairs, drawing on leadership experience from both large pharmaceutical companies and successful biotech start‐ups. Eledon’s board and scientific advisory group include specialists in stem cell biology, clinical development and rare disease advocacy.

Looking ahead, Eledon plans to expand its clinical development network, engage with key opinion leaders and explore strategic partnerships to broaden access for patients with life‐threatening blood disorders. Through its cell therapy platform, the company seeks to deliver transformative treatments that address unmet medical needs and improve long‐term outcomes for individuals worldwide.

Key Stats

• Today's Range: $3.16 to $3.50
• 50-Day Range: $2.60 to $3.42
• 52-Week Range: $2.38 to $5.54
• Volume: 807,185 shs
• Average Volume: 317,286 shs
• Market Capitalization: $204.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Eledon Pharmaceuticals Stock Analysis - MarketRank™

Eledon Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 527th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eledon Pharmaceuticals is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eledon Pharmaceuticals is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eledon Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.53% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eledon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eledon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.53% of the float of Eledon Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Eledon Pharmaceuticals has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELDN Stock Analysis - Frequently Asked Questions

How have ELDN shares performed this year?

Eledon Pharmaceuticals' stock was trading at $4.12 on January 1st, 2025. Since then, ELDN stock has decreased by 17.0% and is now trading at $3.42.

How were Eledon Pharmaceuticals' earnings last quarter?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.20.

Who are Eledon Pharmaceuticals' major shareholders?

Top institutional investors of Eledon Pharmaceuticals include Howard Financial Services LTD. (0.05%).
View institutional ownership trends.

How do I buy shares of Eledon Pharmaceuticals?

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eledon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELDN
• CIK: 1404281
• Web: novustherapeutics.com
• Phone: (949) 238-8090
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eledon Pharmaceuticals: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +163.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.18 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -79.54%
• Return on Assets: -41.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.90
• Quick Ratio: 13.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.98 per share
• Price / Book: 1.73

Miscellaneous

• Outstanding Shares: 59,880,000
• Free Float: 52,517,000
• Market Cap: $204.79 million
• Optionable: Optionable
• Beta: -0.16